Alopecia Hair loss, alopecia, baldness
Conditions
Sponsors
Kikuchi Mamoru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with written informed consent. 2. Patiens are at least 18 years of age 18 at the time of informed consent. 3. Patients affected alopecia and want to receive regenerative therapy.
Exclusion criteria
Exclusion criteria: 1. Patients with HbA1c(NGSP) more than 10.0 with the medication for diabetes. 2. Patients with systemic infection. 3. Patients with severe anemia. 4. Patients with malignancy, or within 5 years after recover from malignant tumor (10 years after breast cancer), except for cutaneous basal cell carcinoma. 5. Patients with hematopoietic disorders such as leukemia, myeloproliferative disease, marr ow dysplasia syndrome. 6. Pregnant women. 7. Patients infected with HIV, active HBV, HCV, HTLV, or syphilis in screening test. 8. Patients not expect to live for a year or more. 9. Patients enrolled in any other clinical trial within 90 days before informed consent. 10. Patients who can't consent not to change medication. 11. Any other reason that the Clinical Researchers may have for considering a case unsuit able for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the safety of Ricacell injection for alopecia patients. side effects, adverse events, serious advese events, clinical laboratory data, vital sign | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the efficacy of Ricacell injection for alopecia patients. 1. Evaluation of the changes in appearance. 2. Changes of the number of hairs, hair density, hair diameter, scalp pigmentation, hair cycle. Evaluation is done by using Derm ascopy or Trichoscopy. 3. QOL and patients satisfaction. 4. Changes of Hamilton-Norwood scale, Sincl air scale, Ludwig scale. | — |
Countries
Japan
Contacts
Public ContactSoichiro Honda
Re-cellf
Outcome results
None listed